{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011845","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.838875+00:00","generated_at":"2026-05-17T08:28:14.305289+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProMIS Neurosciences advances PMN310 to final dose cohort in Alzheimer's Phase 1b trial","bullets":["DSMB unanimously recommends proceeding to third and final dose escalation cohort (20 mg/kg) after safety review.","Cohort 2 fully enrolled; no cases of amyloid-related imaging abnormalities (ARIA) observed to date.","Enrollment of Cohort 3 underway; 6-month interim data expected Q2 2026, final top-line results Q4 2026.","Trial to enroll 128 patients with comprehensive biomarker panel including pTau217, NfL, GFAP, and synaptic markers.","PMN310 holds FDA Fast Track designation; CEO to present at H.C. Wainwright conference on Sept 10, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011845","json":"https://secwatch.observer/filing/0001558370-25-011845.json","markdown":"https://secwatch.observer/filing/0001558370-25-011845.md","text":"https://secwatch.observer/filing/0001558370-25-011845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/0001558370-25-011845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/pmn-20250903x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:28:14.305289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}